Trial · NCT03403205
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W) | Cohort 1: ALXN1840 | 2.50 | Standard Error 0.150 | micromoles (µmol)*hours (hr)/liter (L) | |
| Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W) | Cohort 1: SoC Therapy | 0.87 | Standard Error 0.204 | micromoles (µmol)*hours (hr)/liter (L) | |
| Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W) | Cohort 2: ALXN1840 | 4.76 | Standard Error 0.319 | micromoles (µmol)*hours (hr)/liter (L) | |
| Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W) | Cohort 2: SoC Therapy | 0.96 | Standard Error 0.487 | micromoles (µmol)*hours (hr)/liter (L) | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Cohort 1: ALXN1840 | 89 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Cohort 1: SoC Therapy | 41 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Cohort 2: ALXN1840 | 30 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Cohort 2: SoC Therapy | 12 | Participants | ||
| Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48 | Cohort 1: ALXN1840 | -0.7 | Standard Deviation 2.75 | units on a scale | |
| Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48 | Cohort 1: SoC Therapy | 0.0 | Standard Deviation 2.31 | units on a scale | |
| Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48 | Cohort 2: ALXN1840 | -0.5 | Standard Deviation 3.23 | units on a scale | |
| Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48 | Cohort 2: SoC Therapy | -1.8 | Standard Deviation 4.63 | units on a scale | |
| Change From Baseline in UWDRS Part III Total Score at Week 48 | Cohort 1: ALXN1840 | -2.24 | Standard Deviation 7.458 | units on a scale | |
| Change From Baseline in UWDRS Part III Total Score at Week 48 | Cohort 1: SoC Therapy | -1.59 | Standard Deviation 6.188 | units on a scale | |
| Change From Baseline in UWDRS Part III Total Score at Week 48 | Cohort 2: ALXN1840 | -2.06 | Standard Deviation 9.843 | units on a scale | |
| Change From Baseline in UWDRS Part III Total Score at Week 48 | Cohort 2: SoC Therapy | 1.55 | Standard Deviation 5.889 | units on a scale | |
| Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48 | Cohort 1: ALXN1840 | -0.165 | Standard Deviation 0.7620 | units on a scale | |
| Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48 | Cohort 1: SoC Therapy | -0.102 | Standard Deviation 0.5467 | units on a scale | |
| Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48 | Cohort 2: ALXN1840 | -0.090 | Standard Deviation 0.8464 | units on a scale | |
| Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48 | Cohort 2: SoC Therapy | 0.227 | Standard Deviation 0.4214 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03403205/results